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Background: In Japan, both incidence and mortality rates of cancers have continuously increased and medical
costs are growing more rapidly than the overall economy of Japan. However, there is no consensus threshold for
cost-effectiveness in medical care, and few studies have investigated cost-effectiveness of medical care in Japan.
The present study was to determine the direct costs of molecular-targeting drugs that were recently approved
in Japan through simple and quantitative calculations. Thus, we calculated an incremental cost-effectiveness
ratio (ICER) and the cost per life-year gained (LYG) by using reported data from randomized clinical trials for
various cancers.
Methods: Between 2008 and 2011, we reviewed seven molecular-targeting drugs that were approved for
treatment of five cancers in Japan. These drugs included Bevacizumab, sorafenib, sunitinib, temsirolimus, Lapatinib,
and panitumumab. Direct cost, ICER, and LYG of the drugs were estimated from the randomized phase III clinical
trial data referred to in package leaflets. Effectiveness was defined as the prolongation of both median overall
survival (OS) and progression-free survival (PFS). Costs were calculated as those of molecular-targeting drugs.
Subsequently, ICER was based on 1-month increases in both OS and PFS periods and 1% increases in OS, and LYG
was determined.
Results: Direct costs ranged from ¥724,804 ($9,060) to ¥1,506,628 ($18,833). ICERs of the drugs ranged from
¥724,804 ($9,060) to ¥1,506,628 ($18,833) for a 1-month increase in OS. For each month of PFS, ICERs ranged from
¥372,243 ($4,653) to ¥7,399,877 ($92,498). The costs of Bevacizumab and sorafenib for treatment of HCC per 1%
increase in OS were ¥376,657 ($4,708) and ¥313,733 ($3,922), respectively. LYG ranged from ¥8,697,650 ($108,721) to
¥18,079,530 ($225,994).
Conclusions: Some molecular-targeting drugs are not cost-effective. Considering ethical and moral issues,
we should establish economic endpoints to approve new drugs in Japan.
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In Japan, both incidence and mortality rates of cancers
have continuously increased since the 1960s, with more
than 357,000 cancer fatalities in 2011 [1]. The Ministry
of Health, Labour and Welfare approves new anticancer
drugs depending on the results of clinical trials. Medical
costs are growing more rapidly than the overall econo-
my of Japan. Japanese medical costs in 2010 came to
¥37,400 billion ($468 billion), ¥3,500 billion ($44 billion)
of which was spent on cancer [2]. With increasing* Correspondence: tebara@saitama-med.ac.jp
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reproduction in any medium, provided the ornumbers of cancer patients, medical costs have conti-
nued to increase over recent years. However, there is no
consensus threshold for cost-effectiveness in medical
care, and few studies have investigated cost-effectiveness
of medical care in Japan.
The primary objective of the present study was to de-
termine the direct costs of molecular-targeting drugs
that were recently approved in Japan through simple
and quantitative calculations. Thus, we calculated an in-
cremental cost-effectiveness ratio (ICER) and the cost
per life-year gained (LYG) by using reported data from
randomized clinical trials for various cancers.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Between 2008 and 2011, we reviewed seven molecular-
targeting drugs that were approved for treatment of five
cancers in Japan. These included Bevacizumab for non-
squamous-cell and non-small-cell lung cancer (NSCLC),
everolimus for metastatic renal cell carcinoma (RCC),
sorafenib for advanced clear-cell RCC and hepatocellular
carcinoma (HCC), sunitinib or temsirolimus for meta-
static RCC, Lapatinib for locally advanced or metastatic
breast cancer, and panitumumab for metastatic colorec-
tal cancer. ICER and LYG of the drugs were compared
using clinical data from randomized phase III clinical tri-
als, which were referred to in package leaflets [3]. Med-
ical effectiveness was defined as the prolongation of
both median overall survival (OS) and progression-free
survival (PFS). Medical costs were calculated from the
costs of molecular-targeting drugs and the median or
mean duration of treatments. In reports that did not
present median or mean treatment duration, it was as-
sumed that treatments continued until the occurrence of
disease progression, and treatment duration was esti-
mated accordingly. For simplicity, we assumed that aver-
age drug-dosing regimens were those appropriate for a
60-year-old male or female patient because the incidence
of cancer is higher around this age range. Based on a
report by the National Health and Nutrition Survey, bo-
dy surface areas of male and female patients calculated
from heights and weights of 165 cm and 61 kg and 152
cm and 54 kg were 1.7 m2 and 1.5 m2, respectively [4].
Drug costs were calculated for the year 2012 based on
the medical fee given in the National Health Insurance
drug price list [5]. Other direct and indirect costs were
not included in this analysis. Subsequently, ICER, which
is expressed as additional costs of new treatment per
gain in clinical outcome, was calculated as follows.
ICER = Cost (A) − Cost (B)/effectiveness (A) −
effectiveness.
(B) ICER was based on 1-month increases in both OS
and PFS periods and 1% increases in OS. LYG was alsoTable 1 Drugs and details of clinical trials
No. Drug (Brand name) Disease Reg
1 Bevacizumab (Avastin) Non-SQ, NSCLC # Pac
plus
2 Everolimus (Afinitor) Renal cell carcinoma Eve
3 Sorafenib (Nexavar) Renal cell carcinoma Sora
4 Sorafenib (Nexavar) Hepatocellular carcinoma Sora
5 Sunitinib (Sutent) Renal cell carcinoma Sun
6 Temsirolimus (Torisel) Renal cell carcinoma Tem
7 Lapatinib (Tykerb) Breast carcinoma Cap
8 Panitumumab (Vectibix) Colorectal carcinoma Pan
#; non-squamous-cell, non–small-cell lung cancer.
*; best supportive care.calculated. US dollar costs were converted to Japanese
Yen by multiplying by 80.
Findings
Among trials of the seven drugs, some compared mo-
lecular-targeting drugs with placebo or best supportive
care (BSC), while others compared molecular-targeting
drugs with previously established drugs. Representative
phase III trials are summarized in Table 1. Trial 1 de-
termined whether addition of Bevacizumab to paclitaxel
and carboplatin improved survival of patients with me-
tastatic non-squamous-cell and NSCLC [6]. Trials 2–4
evaluated everolimus for metastatic RCC and sorafenib
for advanced clear-cell RCC and HCC and made com-
parisons with placebo-treated patients [7-9]. Trials 5 and
6 compared the efficacy of sunitinib or temsirolimus for
metastatic RCC with that of interferon alpha [10,11].
Trial 7 determined whether addition of Lapatinib to
capecitabine improved survival of patients with HER2-
positive, locally advanced, or metastatic breast cancers
[12], and panitumumab was compared with BSC in pa-
tients with metastatic colorectal cancer [13]. Table 2
shows drug costs estimated by published studies. The dir-
ect costs of Bevacizumab, everolimus, sorafenib for RCC,
sorafenib for HCC, sunitinib, temsirolimus, Lapatinib,
and panitumumab were ¥3,013,255 ($37,666); ¥2,415,109
($30,189); ¥3,581,292 ($44,766); ¥3,451,063 ($43,138);
¥6,153,336 ($76,917); ¥3,136,794 ($39,210); ¥1,787,170
($22,340); and ¥1,151,092 ($14,389), respectively. OS and
PFS data from the trials are summarized in Table 3.
In studies of Bevacizumab and Lapatinib [6,12], cost
differences (cost (A) − cost (B)) were presumed to be
equivalent to the cost of Bevacizumab and Lapatinib be-
cause these studies estimated additional effect of these
drugs to control arm. When control arms were placebo
or BSC [7-9,13], the cost (B) of the formulation was set
at zero. In contrast, cost (B) in trials of sunitinib and
temsirolimus [10,11] reflected the cost of interferon





Sandler et al. [6]
rolimus Placebo Motzer et al. [7]
fenib Placebo Escudier et al. [8]
fenib Placebo Llover et al. [9]
itinib Interferon alpha Motzer et al. [10]
sirolimus Interferon alpha Kwitkowski et al. [11]
ecitabine plus Lapatinib Capecitabine Geyer et al. [12]
itumumab BSC* Cutsem et al. [13]
Table 2 Estimated drug costs





1 Bevacizumab 15 mg/kg every 3 weeks 900 mg every 3 weeks ¥430,465 ($5,381) 7 cycles ¥3,013,255 ($37,666)
2 Everolimus 10 mg daily 10 mg = 2 tablets ¥25,422 ($328) 95 days ¥2,415,109 ($30,189)
3 Sorafenib* 800 mg daily 800 mg = 4 tablets ¥21,705 ($271) 5.5 months ## ¥3,581,292 ($44,766)
4 Sorafenib** 800 mg daily 800 mg = 4 tablets ¥21,705 ($271) 5.3 months ¥3,451,063 ($43,138)
5 Sunitinib 50 mg daily on days 1–28
of a 42-day cycle
50 mg = 4 capsules ¥34,185 ($427) 6.0 months ¥6,153,336 ($76,917)
6 Temsirolimus 25 mg weekly 25 mg = 1 vial ¥132,915 ($1,661) 5.5 months ## ¥3,136,794 ($39,210)
7 Lapatinib 1250 mg daily on days 1–14
of a 21-day cycle
1250 mg = 5 tablets ¥8,100($101) 11 cycles ## ¥1,787,170 ($22,340)
8 Panitumumab 6 mg/kg on every 2 weeks 360 mg every 2 weeks ¥287,773 ($3,597) 4 cycles ¥1,151,092 ($14,389)
#; A 60-year-old male or female patient was considered. The detail was described in the text.
##; Median or mean cycles/days was not mentioned in the literatures. Therefore, these durations were assumed from the progression-free survival period because
the treatment continued until the occurrence of disease progression, unacceptable adverse events, or withdrawal of consent.
*; for renal cell carcinoma.
**; for hepatocellular carcinoma.
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1 month, ICERs of Bevacizumab, sorafenib for HCC,
and temsirolimus were ¥1,506,628 ($18,833); ¥1,053,321
($13,167); ¥1,232,523 ($15,407); and ¥724,804 ($9,060),
respectively. ICERs of Bevacizumab and sorafenib for
HCC were ¥376,657 ($4,708) and ¥313,733 ($3,922)
per 1% increase in OS. For each month of PFS, ICERs
of Bevacizumab, everolimus, sorafenib for RCC or
HCC, sunitinib, temsirolimus, Lapatinib, and panitumu-
mab were ¥1,772,503 ($225,156); ¥1,150,052 ($14,376);
¥1,326,404 ($16,580); ¥915,546 ($11,444); ¥1,087,206
($13,590); ¥372,243 ($4,653); and ¥7,399,877 ($92,498),
respectively. LYGs with Bevacizumab, sorafenib for
HCC, and temsirolimus were ¥18,079,530 ($225,994);
¥12,639,854 ($157,998); and ¥14,790,271 ($184,878)–
¥8,697,650 ($108,720), respectively (Table 4).Table 3 OS and PFS in the trials
No Drug Median OS (months) Median PFS (months)
Control arm Test arm Control arm Test arm
1 Bevacizumab 10.3 15% * 12.3 23% * 4.5 6.2
2 Everolimus # # 1.9 4.0
3 Sorafenib+ 15.9 19.3 2.8 5.5
4 Sorafenib++ 7.9 33%** 10.7 44%** 4.9## 4.1##
5 Sunitinib # # 5.0 11.0
6 Temsirolimus 7.3 10.9 3.1 5.5
7 Lapatinib # # 4.4 8.4
8 Panitumumab # # 7.3 8.0
#; Not mentioned in the literatures.
##; The median time to symptomatic progression.
*; at 2 years.
**; at 1 year.
+; for renal cell carcinoma.
++; for hepatocellular carcinoma.Discussion
Substantial increase in the cost of cancer care is a global
concern. The American Society of Clinical Oncology pub-
lished guidelines that can be used to assess the costs of
high quality cancer treatment [14]. Cost-effectiveness ana-
lyses compare ratios of incremental cost and incremental
effectiveness of various strategies [15]. Quality-adjusted
life years (QALYs) are commonly used to estimate the
cost–utility of medical care. In the United States and
United Kingdom, $50,000–100,000 and £20,000–30,000
per QALY are considered acceptable thresholds for
cost-effectiveness [16]. A Japanese study on willingness to
pay for one additional QALY suggests that ¥5,000,000
($62,500) is an appropriate threshold [16]. However, few
investigations examine medical cost-effectiveness, and
consensus thresholds have not been established in Japan.
Determination of thresholds for cost-effectiveness in
medical care is very difficult. Fojo et al. suggested that
research studies with the ability to detect survival advan-
tages of 2 months or less should only test interventions
that cost less than $20,000 per course of treatment [17].
The present study shows that most molecular-targeting
drug regimens cost more than ¥1,000,000 ($12,500) per
1-month gain in survival. Hence, these drugs have poor
cost-effectiveness according to Fojo’s standard.
Among cancer treatments, radiation therapy has the
greatest potential for cost-effectiveness in Japan [18].
The cost-effectiveness of carbon ion radiotherapy (CIRT)
and conventional multimodal therapies was compared in
Japanese patients with locally recurrent rectal cancers
[19]. ICER per 1% increase in survival for CIRT was
¥6,428 ($80), much cheaper than that for Bevacizumab
and sorafenib (¥376,657 and ¥313,733, respectively).
Molecular-targeting drugs offer novel and attractive
strategies for improving patient survival and quality of
Table 4 Incremental cost-effective ratio










ICER per 1 month
increase in PFS
LYG
1 Bevacizumab ¥3,013,255 ($37,666) 2.0 8% at 2 years 1.7 ¥1,506,628 ($18,833) ¥376,657 ($4,708) ¥1,772,503 ($22,156) ¥18,079,530 ($225,994)
2 Everolimus ¥2,415,109 ($30,189) ## 2.1 ¥1,150,052 ($14,376)
3 Sorafenib+ ¥3,581,292 ($44,766) 3.4 2.7 ¥1,053,321 ($13,167) ¥1,326,404 ($16,580) ¥12,639,854 ($157,998)
4 Sorafenib++ ¥3,451,063 ($43,138) 2.8 11% at 1 year −0.8 ¥1,232,523 ($15,407) ¥313,733 ($3,922) Dominated ¥14,790,271 ($184,878)
5 Sunitinib ¥5,493,276 ($68,666) * 6.0 ¥915,546 ($11,444)
6 Temsirolimus ¥2,609,295 ($32,616) 3.6 2.4 ¥724,804 ($9,060) ¥1,087,206 ($13,590) ¥8,697,650 ($108,720)
7 Lapatinib ¥1,787,170 ($22,340) ** 4.0 ¥372,243 ($4,653)
8 Panitumumab ¥1,151,092 ($14,389) *** 0.2 ¥7,399,877 ($92,498)
OS; overall survival, PFS; progression-free survival, ICER; incremental cost-effective ratio, LYG; cost per life-year gained.
#; See the formulation (*) in Materials and methods and Results.
##; At the time of the analysis, median overall survival had not been reached for the everolimus group. There was no significant difference between the groups in terms of overall survival.
*; At the time of the analysis, median overall survival was not reached in either group.
**; Thirty-six deaths occurred in the Lapatinib group and 35 occurred in the control group (P = 0.72). OS curves in the literature seem to indicate no definite difference.
***; The literature mentioned that no difference was observed in OS.
+; for renal cell carcinoma.
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inhibitor of BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic
myeloid leukemia and is considered a standard first line
treatment [20]. On the other hand, molecular-targeting
drugs are often only effective in a subset of patients. For
example, anti-epidermal growth factor receptor anti-
bodies should not be administered to colorectal carcin-
oma patients with KRAS mutations in codons 12 or 13
[21], although improved cost-effectiveness can be de-
monstrated for the remaining subset of patients.
Cost containment in oncology is a moral issue, and
cost-effectiveness analyses are often recommended for
determining how to best allocate resources. However,
cost-effectiveness analyses often make prescriptions
that are at odds with a sense of justice. That is, cost-
effectiveness analyses reveal findings that maximize
the average outcome but are indifferent to the statistical
distribution of these outcomes. Hence, it is unethical to
control medical costs with bureaucratic mechanisms [22].
As medical economic evaluations are relatively specific
to individual health care systems, translation of the re-
sults of one economic study to different health care sys-
tems can be problematic [15]. Tsuchiya et al. performed
cost-effectiveness analyses of consolidation therapy with
Pemetrexed for NSCLC in Japan [23]. Their data indi-
cated difficulties in use of consolidation therapy as the
standard of care for Japanese patients who are covered
by general medical insurance. In contrast, a US study re-
vealed consolidation therapy to be cost-effective. We cal-
culated the direct costs of molecular-targeting drugs in
the Japanese medical treatment fee system and devised a
simple, reliable, and quantitative method, allowing phy-
sicians to re-calculate and estimate cost-effectiveness
using drug costs that are specific to local health care
systems.
The lack of QALY analyses is a limitation of the pre-
sent study. However, the reliability of QALY estimates
are limited by methodological variations in measure-
ments of utilities [24], and how well the QALY system
actually reflects patient preferences is still debated [25].
Another limitation of this study is that we only calcu-
lated molecular-targeting drug costs and did not include
other direct medical costs such as premedication and
supportive therapy, direct non-medical costs such as
transportation, and indirect costs such as work loss.
However, use of molecular-targeting drugs could add
costs associated with adverse events.
Conclusions
We have devised a simple and reliable method for es-
timating cost-effectiveness of novel chemotherapeutic
agents and revealed poor cost-effectiveness of molecular-
targeting drugs in Japan. Patient drug selections that aremade with consideration of cost-effectiveness will save
limited health care resources. Considering associated
ethical and moral issues, economic endpoints for new
drug approvals are required in Japan.
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